Cite
HARVARD Citation
Sweet, K. et al. (2021). A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 62 (13), pp. 3192-3203. [Online].